Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Which index fund performed best this year? Review top performers, volatility, and potential shifts to inform your next move.
26,831 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
April’s jobs data shows a broad recovery in payrolls, but the information and finance sectors continue to lag, highli...
Poly Truth is rolling out an AI-powered intelligence layer for prediction markets, promising data-driven insights on ...
An FDA leadership shakeup deepens as Tracy Hoeg publicly says she was fired, prompting questions about regulatory dir...
As Nvidia's earnings hours away approach, investors crave clarity on AI demand, profitability, and guidance. This pie...
A new advocacy group backing Kalshi’s prediction market efforts has publicly launched in Washington, with former Whit...
Three fintech names offer steadier paths than SoFi as the sector shifts toward profitability, buybacks, and dividends...
A Roth IRA can unlock tax-free dividend income. With a $750,000 balance, investors could target about $42,000 to $48,...
A prediction-market operator flagged unusual bets tied to a former U.S. representative ahead of a State of the Union ...
May payrolls rose by 172,000, with April revisions lifting the prior month. Unemployment stayed at 4.3% as the Fed we...
A growing cohort of European women occupy the corner offices of major firms in 2026, driving changes in governance an...
An elderly shopper nearly handed over $18,000 in cash to a scam caller. A vigilant store clerk stepped in, proving on...